ALC Stock Chart & Stats
$67.91
$0.22(0.32%)
At close: 4:00 PM EDT
$67.91
$0.22(0.32%)
Day’s Range― - ―
52-Week Range$61.84 - $87.64
Previous Close$87.56
Volume1.36M
Average Volume (3M)1.98M
Market Cap
$36.66B
Enterprise Value$29.78K
Total Cash (Recent Filing)$1.46B
Total Debt (Recent Filing)$5.31B
Price to Earnings (P/E)56.6
Beta0.71
Next Earnings
Nov 10, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)1.29
Shares Outstanding499,700,000
10 Day Avg. Volume2,110,904
30 Day Avg. Volume1,977,258
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$89.91Price Target Upside32.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)3.53
Revenue Forecast (FY)$11.22B
Bulls Say, Bears Say
Bulls Say
Broad-based Growth And Market ShareGrowth across Surgical and Vision Care reduces reliance on one product or market. Record contact-lens share, strong UNITY adoption and broad geographic performance support durable customer relationships and recurring demand from procedures and replacement cycles.
Product Innovation Supports Margins And GrowthNew products including TRYPTYR, Valeda, PanOptix Pro and UNITY can expand Alcon’s addressable market and product mix. The raised profitability outlook suggests innovation and scale may support operating leverage beyond a single quarter.
Strong Cash Generation And Conservative LeverageImproving free cash flow provides resources for product development, manufacturing investment and shareholder returns without requiring aggressive borrowing. Low leverage also gives Alcon flexibility to absorb industry volatility and fund long-term expansion.
Bears Say
Recent Profitability And Returns Have WeakenedThe decline in net margin and ROE indicates that recent revenue growth has not translated fully into shareholder returns. If operating costs, pricing pressure or mix issues persist, they could limit the sustainability of projected earnings improvement.
Competition And Slower Surgical AdoptionCompetitive launches and reimbursement-driven adoption challenges can restrain Alcon’s Surgical segment, where equipment placements and implant volumes support recurring consumables. Persistent pressure could weaken growth and reduce operating leverage in this strategic business.
Pipeline Execution SetbacksThe PowerVision discontinuation removes a potential long-term innovation pathway, while UNITY DX delays defer expected revenue and adoption benefits. Together, these issues show that clinical validation and scalable manufacturing remain execution risks for the pipeline.
Alcon News
ALC FAQ
What was Alcon’s price range in the past 12 months?
Alcon lowest stock price was $61.84 and its highest was $87.64 in the past 12 months.
What is Alcon’s market cap?
Alcon’s market cap is $36.66B.
When is Alcon’s upcoming earnings report date?
Alcon’s upcoming earnings report date is Nov 10, 2026 which is in 78 days.
How were Alcon’s earnings last quarter?
Alcon released its earnings results on Aug 10, 2026. The company reported $0.852 earnings per share for the quarter, beating the consensus estimate of $0.756 by $0.096.
Is Alcon overvalued?
According to Wall Street analysts Alcon’s price is currently Undervalued.
Does Alcon pay dividends?
Alcon pays a Annually dividend of $0.359 which represents an annual dividend yield of 0.49%. See more information on Alcon dividends here
What is Alcon’s EPS estimate?
Alcon’s EPS estimate is 0.89.
How many shares outstanding does Alcon have?
Alcon has 499,700,000 shares outstanding.
What happened to Alcon’s price movement after its last earnings report?
Alcon reported an EPS of $0.852 in its last earnings report, beating expectations of $0.756. Following the earnings report the stock price went up 2.336%.
Which hedge fund is a major shareholder of Alcon?
Currently, no hedge funds are holding shares in ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$89.91 (32.39% Upside)
$89.91 (32.39% Upside)
Blogger Sentiment
Bullish
ALC Sentiment 89%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 251.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.6%
Last 30 Days ▲ 33.6%
Last 30 Days ▲ 33.6%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.74%
12-Months-Change
Fundamentals
Return on Equity
0.49%
Trailing 12-Months
Asset Growth
-0.92%
Trailing 12-Months
Company Description
Alcon
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
ALC Company Deck
ALC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a clearly positive operational and financial quarter: 7% consolidated sales growth, strong equipment performance (UNITY), margin expansion (+250 bps gross margin, +160 bps operating margin), EPS and cash-flow strength, and multiple successful new-product introductions (PanOptix Pro, TRYPTYR, Valeda). Notable negatives included the discontinuation of the PowerVision accommodating IOL program, slower growth in implantables and certain glaucoma products, a few one-time margin items and manufacturability timing for UNITY DX. On balance, the positives — consistent revenue and margin expansion, robust cash generation and multiple high-potential product rollouts and market-share gains — outweigh the setbacks.View all ALC earnings summariesALC Stock 12 Month Forecast
Average Price Target
$89.91
▲(32.39% Upside)
Technical Analysis
Roche Holding AG
―
Straumann Holding AG
―
Siegfried Holding AG
―
Tecan Group AG
―
medmix AG
―
Ownership Overview
―
Insiders
12.32% Mutual Funds
16.57% Other Institutional Investors
53.79% Public Companies and
Individual Investors